Zhuhai United Labs starts first human trial of TUL108, an injectable
The Phase 1 healthy-volunteer study will test single and multiple ascending doses of TUL108, with no target or mechanism yet on record.
Executive Summary
- Zhuhai United Laboratories has registered a Phase 1 study to test TUL108 for Injection in healthy volunteers, its first appearance in human testing.
- The study is built around single and multiple ascending doses, the standard structure for establishing a compound's safety and tolerability before it moves into a target patient population.
- The drug's target, mechanism, and intended disease remain unnamed at this stage, which limits how the readout can be sized against a competitive field.
- The trial is one of three studies in the sponsor's active portfolio, positioning TUL108 as an early-stage addition rather than a flagship program with an established track record.
The filing
Zhuhai United Laboratories Co., Ltd. added a new Phase 1 study to test the safety, tolerability, and pharmacokinetics of TUL108 for Injection, according to the registry record posted July 22, 2026. The trial has not yet started recruiting and is set to begin July 30, 2026, running through a primary completion date of December 30, 2026, an interval of roughly five months consistent with a compact single- and multiple-ascending-dose design. NCT07719257+1Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)NCT07719257Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)Jul 22, 2026
The design
The study plans to enroll 72 healthy adults aged 18 to 45 across a single site in China, split across four arms under double masking. Its primary outcome measures are the incidence of adverse events and serious adverse events, tracked from Day 1 to Day 4 in the single-ascending-dose portion and Day 1 to Day 11 in the multiple-ascending-dose portion. That two-part structure, and the use of randomization and masking rather than an open-label design, is a more built-out approach than the single-arm safety studies common at this stage, though the trial's target, mechanism of action, and intended indication are not yet named in the registry. NCT07719257Evaluation of the Safety, Tolerability and Pharmacokinetics of TUL108 for Injection in Healthy Participants (SAD/ MAD)NCT07719257
Where TUL108 sits
TUL108 has no other trial on record beyond this study, and no competitor program sharing the drug name appears in the current trial landscape. No FDA approval history or regulatory designation is on record for the compound. Because the target and mechanism are not yet disclosed, the drug cannot yet be placed against a specific competitive field or standard of care; its position will become assessable once the sponsor names the biology TUL108 is meant to act on.
Sponsor track record
Zhuhai United Laboratories carries three trials in its total portfolio: one completed, one recruiting, and this new one not yet recruiting. That is a modest, unremarkable base for judging execution, and the registry shows no prior terminations tied to the sponsor.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.